**PRODUCT DATA SHEET**

**ALX-804-590F**

**M30 CytoDEATH™, mAb (fluorescein conjugate)**

**Product Number/Sizes**
ALX-804-590F-T200 200 tests FITC

**Product Specifications**
- **CONCENTRATION:** 0.05mg/ml
- **FORMULATION:** Liquid. In 200μl PBS containing 0.1% BSA, PEG, sucrose and 0.09% sodium azide.
- **CLONE:** M30
- **ISOTYPE:** Mouse IgG2b
- **IMMUNOGEN:** CK18 (cytokeratin 18) fragments purified from supernatant from human carcinoma cell line WiDr CCL218.
- **SPECIFICITY:** Recognizes the CK18-Asp196 neo-epitope (M30) on human, monkey and bovine caspase-cleaved CK18. Does not cross-react with intact CK18.
- **APPLICATION:** Flow Cytometry
  - Immunocytochemistry
  - Immunohistochemistry (frozen sections; paraffin sections)
    - (Only if used with an additional secondary signal enhancing reagent!)
    - A dilution of 1:100 in incubation buffer is generally recommended. Optimal conditions must be determined individually for each application.
- **SHIPPING:** SHIPPED ON BLUE ICE
- **LONG TERM STORAGE:** +4°C
- **HANDLING:** After opening, prepare aliquots and store at -20°C.
  - Avoid freeze/thaw cycles.
- **MANUFACTURER:** Manufactured by Peviva AB.

*Figure:* HeLa cells that received combined treatment with CHX and TRAIL show a sustained and strong caspase activity and concomitant CK18-NE accumulation as detected by the M30 CytoDEATH™ (Prod. No. ALX-804-590) Fluorescein antibody.
**Figure**: Apoptosis of human cervical carcinoma HeLa cells treated with recombinant human TRAIL was quantified with M30 CytoDEATH™ (Prod. No. ALX-804-590) in flow cytometry. Left) M30 CytoDEATH™-Fluorescein; Right) M30 CytoDEATH™+GAM Fluorescein. M30 CytoDEATH™ antibodies were used at 1µg/ml in a 100µl sample size.

**Product Literature References**


Fas ligand expression by maternal decidual cells is negatively correlated with the abundance of leukocytes present at the maternal-fetal interface Q. Qiu, et al. J. Reprod. Immunol. 65 121 (2005)


Oncosis represents the main type of cell death in mouse models of cholestasis P. Fickert, et al. J. Hepatol. 42 378 (2005)


For a comprehensive bibliography please consult PubMed

**Background/Technical Information**

Cytokeratin 18 expression has been shown but is not limited to cells and tissues from lung, breast, intestine, gut, colon, kidney, pancreas, bladder, trophoblasts … etc. The M30 CytoDEATH™ monoclonal antibody has been shown in numerous independent studies to be specific to the CK18-Asp396 caspase cleavage site (neo-epitope (M30)) and represents a well-established, validated apoptosis marker that does not react with viable or necrotic cells. M30 CytoDEATH™ detects human, monkey and bovine apoptotic epithelial cells and tissues and has been validated for many applications including immunohistochemistry of formalin-fixed paraffin-embedded (FFPE) tissues. Apoptosis detection using M30 CytoDEATH™ has been described in several publications to serve as a superior technique compared to TUNEL or detection of γH2AX phosphorylation. Assessment of apoptosis by immunohistochemical markers compared to cellular morphology in ex vivo stressed colon mucosa under conditions of DNA-damage may be repaired and results in false-positive counts of apoptotic cells. In addition has modest or transient caspase activation without the cleavage of death substrates been attributed to non-suicidal processes such as proliferation, differentiation and inflammation.

For more information on procedures and materials required please see also the Original Manufacturers Product Description (click here to download pdf for M30 CytoDEATH™ Monoclonal Antibody (Fluorescein))
WARNING: THIS PRODUCT IS NOT INTENDED OR APPROVED FOR HUMAN, DIAGNOSTICS OR VETERINARY USE. USE OF THIS PRODUCT FOR HUMAN OR ANIMAL TESTING IS EXTREMELY HAZARDOUS AND MAY RESULT IN DISEASE, SEVERE INJURY, OR DEATH.

MATERIAL SAFETY DATA: This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet.

WARRANTY AND LIMITATION OF REMEDY: Enzo Life Sciences AG, Enzo Life Sciences International, Inc., Enzo Life Sciences GmbH, Enzo Life Sciences (UK) Ltd., and Enzo Life Sciences BVBA (“The Companies”) make no warranty of any kind, expressed or implied, including, but not limited to, the warranties of fitness for a particular purpose and merchantability, which extends beyond the description of the chemicals on the face hereof, except that the material will meet our specifications at the time of delivery. Buyer’s exclusive remedy and the Companies’ sole liability hereunder shall be limited to refund of the purchase price of, or at the Companies’ option the replacement of, all material that does not meet our specifications. The Companies shall not be liable otherwise or for incidental or consequential damages, including, but not limited to, the costs of handling. Said refund or replacement is conditioned on Buyer giving written notice to the Companies within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within said thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

Revised 24-Oct-11